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The growth in the direct-to-consumer genetic testing industry poses a number of
challenges for healthcare practice, among a number of other areas of concern. Several
companies providing this service send their customers reports including information
variously referred to as genetic ethnicity, genetic heritage, biogeographic ancestry, and
genetic ancestry. In this article, we argue that such information should not be used
in healthcare consultations or to assess health risks. Far from representing a move
toward personalized medicine, use of this information poses risks both to patients as
individuals and to racialized ethnic groups because of the way it misrepresents human
genetic diversity.
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INTRODUCTION
It may seem surprising now to think that not long ago genetic testing was largely confined to
clinical and research contexts. The progressive reduction in the cost of sequencing and genotyping,
coupled with the limited demand for clinically-driven testing in the early 2000s led to companies
marketing and selling their tests directly to consumers to increase sales (1). Direct-to-consumer
(DTC) genetic tests, as the name suggests, most often return results directly to the consumer
without the involvement of a clinician and this industry has grown rapidly in the past two
decades, despite the concerns of clinical geneticists and genetic counselors (2, 3). In 2016, one
study identified 246 different companies who offered some form of an online DNA test, where
74 companies (roughly 30%) offered ancestry services, and 92 (roughly 37%) offered genetic
relatedness services (4). According to the MIT Technology Review, “[t]he number of people who
have had their DNA analyzed with direct-to-consumer genetic genealogy tests more than doubled
during 2017 and now exceeds 12 million, according to industry estimates” (5). Explicitly health-
related direct-to-consumer genetic testing emerged initially within an ambiguous regulatory setting
in many countries (6). In the US context there were no clear regulatory mechanisms in place to
assess the analytical validity, clinical validity, and clinical utility of DTC tests in the early 2000s
when sale of genetic tests was beginning to gather speed (6). Between 2015 and 2017 some large
scale companies in the industry worked to develop the evidence base to support theirmedical claims
and, as a result, in 2017 the US FDA authorized the first DTC genetic test as an approved medical
device, marking the start of a phase some authors have called DTC 2.0 (6). The industry has been
criticized for problems with reported invalidity of health-related results (7), lack of data privacy (8),
and lack of transparency (9).
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There is a definite mismatch between what consumers think
that they are getting from these tests and what the companies
themselves state they are giving to consumers of their products.
This despite the fact a number of companies have issued public
disclaimers, stating that “their services are not meant to be
used as medical advice or as a diagnostic tool” (10). There
is also empirical evidence that concerns about DTC genetic
testing are more prevalent for certain minority groups (11).
Recent work done by sociologists, anthropologists, and historians
illustrates the myriad misunderstandings, miscommunications,
and attempts to deal with historical discrimination between
medical practitioners and marginalized people that have arisen
around the issue of genetic testing (12–14).
One feature of some DTC genetic testing companies’ output
is referred to variously as biogeographical ancestry, genetic
ethnicity, genetic heritage, or genetic ancestry (hereafter genetic
ancestry), suggesting the person’s DNA has been separated
into sections associated with the places or groups from
which the DNA originates. The output normally consists of
a list of percentages associated with particular continents
and/or currently existing countries and/or ethnic/racial groups,
depending on the company. In many cases, a primary motivation
for consumers’ engagement with DTC genetic testing is to
receive this information (10). Advertising for a number of these
companies strongly suggest they will connect the individual to
their own ethnically-inflected history (“Discover your genetic
heritage,” “Trace your DNA. Find your roots,” “Explore your
genetic roots,” “What’s your tribe.”) (15).
Some authors have called for genetic ancestry test results
to be used in healthcare, suggesting this would constitute
“closing a gap” between health-related genetic testing and
genetic ancestry testing (16). Some tests already output ethically-
specific disease risk estimates for consumers based on their
own proprietary ancestry results, meaning the services are
already integrated (17). In this paper, we argue against the
integration of DTC genetic ancestry test results into healthcare
because of the risks to patients—risks that stem from the
invocation of poorly operationalized concepts that misrepresent
the accuracy and validity of these tests. We draw upon
studies and literature from empirical and theoretical sources
that are broadly focused upon DTC genetic ancestry tests,
even though some specific contexts (such as the USA and
UK) are highlighted., drawing on knowledge from studies
of human genetic diversity and social research in the US
and UK.
GENETIC ANCESTRY TEST RESULTS IN
THE CONTEXT OF HUMAN BIOLOGY
Genetic ancestry results, with their percentages by region
and often slick presentation, certainly provide an appearance
of precision to the consumer but this very appearance is
“dangerously seductive and equally misleading” (18). The validity
of the genetic ancestry results of DTC testing have been
questioned and challenged on several grounds. Numerous
news articles, blog posts, and YouTube videos attest to
inconsistencies in results from different companies’ genetic
ancestry tests (19–22), even for the same test’s results for
identical twins (23), and the same test’s results at different
points in time (24). It has been highlighted in a report to the
US Congressional Research Service that the widespread use of
proprietary databases by these companies means the scientific
claims made in genetic testing results cannot be independently
verified (25).
The idea of using genetic data to categorize people into
continental groups to further knowledge about differences in
disease risk by race or ethnicity is not new (26), nor is the
idea that genetic differences underlie differences between white
and racialized populations in terms of physiological aspects
of diseases that occur in both sets of populations (27–29).
However, a large and long-standing body of research refutes the
supposition that epidemiologically-evidenced ethnic differences
in human disease risk, including diseases with a demonstrated
genetic basis and limited geographic distribution, are evidence in
support of the notion of biological race (30, 31). Indeed, repeated
studies of human population genetics for well over 40 years have
concluded that the genetic data do not support the notion of
biological races in humans (29, 32–34) and some geneticists have
called for an end to the use of racial and ethnic categories in
clinical contexts on this basis (29).
Despite this, attempts to reinscribe the notion of biological
race in humans continue, particularly in biomedical and
biotechnology arenas (31, 35, 36). Legal scholar Kahn notes
an increasing trend in conflation of race and genetics in
gene-related patent applications, citing “the strategic use of
race as a genetic category to obtain patent protection and
drug approval” (37). Some have specifically argued that
explicit racial profiling is a positive step toward the much-
promoted ideal of personalized medicine based on the logic
that racial groups differ genetically (38). Indeed a tendency
has been noted in the conceptualization and implementation
of personalized medicine, the tendency for this to become
racialized medicine, with racial categories used as proxies
for specific functional genetic information (36, 39). Because
of what we know about the way human genetic diversity
is apportioned, any scientific inference made which assumes
humans come in “neat racial packages” is not trustworthy and,
as a consequence, the only valid way to understand what is
in a person’s DNA is to study that individual’s DNA (32).
Assumptions about disease that are made because of a racial
classification can result in important negative consequences
for individual patients and inaccurate genetic inferences for
populations (31).
In order to make the meaning of the above statements clearer,
we expand on them here. Barbujani and Pigliucci have pointed
out that any two groups of human beings, divided on any basis,
however arbitrary (e.g., plumbers vs. dentists), will differ to some
extent in average measures of any particular biological trait one
chooses, including genetic traits (e.g., ability to digest milk), and
this does not mean these groups represent important taxonomic
categories (or that ability to digest milk influences choice of
plumbing over dentistry as profession) (32). As Lee et al. write
in Statements 2 and 7 of their ethical principles:
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“Statement 2: We recognize that individuals of two different
geographically defined human populations are more likely to
differ at any given site in the genome than are two individuals of
the same geographically defined population Research in human
genetics has highlighted that there is more genetic variation
within than between human groups, where those groups are
defined in terms of linguistic, geographic, and cultural boundaries
...
Statement 7: We discourage the use of race as a proxy for
biological similarity and support efforts to minimize the use
of the categories of race and ethnicity in clinical medicine,
maintaining focus on the individual rather than the group
Although a broad range of associations between genetic
markers and human traits—including diseases—is emerging,
any accompanying correspondence with race or ethnicity is
statistical.” (29).
Even Feldman et al. who suggest that identifying “all
contributions to a patient’s ancestry can be useful in diagnosing
and treating diseases with genetic influences,” a point with
which we disagree on the basis that all ancestral contributions
cannot, in fact, be identified (see below), note that “attempts to
classify people into broad genetic groups based on the frequency
of specific genes for, say, drug-metabolizing enzymes, are also
likely to be poor predictors of medical outcome (40). As with
racial groupings, the overall variation in the frequencies of such
genes between groups is likely to be less than that within each
group” (40).
Since there is no deterministic connection between being part
of a group of people, whether referred to as a population, ethnic
group, or race, and a particular genotype, genetic ancestry-based
approaches to individual care lack an appropriate theoretical
basis (35) and are thus a risk to individual patients. Although
consumers may approach doctors with the results of their genetic
ancestry tests, requesting that these be taken into account,
doctors should exercise great caution (41), consider the evidence
such as that outlined in this paper, and hopefully conclude that
an ethical and truly personalized medical practice should mean
abandoning invalid ethnicity- or race-based assumptions about
individuals’ relevant genetic characteristics.
Genetic Ancestry Test Results:
Debunking “Ancestry”
The notion of ancestry itself deserves some attention. The term
has inherent temporal ambiguities which others have highlighted
(42). The ancestry tests purport to give information about
ancestry from a time before the grandparental generation but
certainly after the distant time of the first transcontinental
migrant hominin groups since all ancestry results would be
African from that time standpoint (34). Yet the potential of
these tests has hinged upon the notion that there is a coherent
understanding of the term “ancestry.” The term is deployed
throughout the literature, however, upon further examination we
find that there are important conceptual problems with its use.
One clear example of this comes from the landmark
Rosenberg et al. paper on the structure of human populations
(42). In their paper, the authors utilize a number of different
conceptions of the term “ancestry” without providing any sort
of robust operationalizable definition of the term. Included in the
article are “self-reported ancestry,” “genetic ancestry,” “Mongol
ancestry,” “self-reported population ancestry,” and “genetically
inferred ancestry” (42). The use of these terms without any
sort of clarification is problematic. How exactly are medical
practitioners and biomedical researchers supposed to understand
the classificatory permutations of the concept ancestry?
One of the only attempts to clarify what the term “ancestry”
means is found in Via et al. (43). In their article, however,
their attempts to clarify the term fail to make any substantial
progress. To note, the authors state that it is important to
find a different term to use in place of “race” or “ethnicity”
for biomedical research and the authors propose the use of
genetic ancestry as an alternative, of which DTC ancestry kits are
ostensibly a developing part. Via et al. (43) proceed to state that
their definition can be defined on several levels: biogeographical
(i.e., African vs. Asian); geographical (i.e., south-east Asian vs.
northern European); geopolitical (i.e., Cambodian vs. Swedish);
and cultural (i.e., Jewish vs. Berber) (43). Additionally, they state
that determinations of ancestry can also be varied: they can
be self-identified; identified by an observer; or estimated from
genetic data. Lastly, in an attempt to provide a final clarification,
the authors state that ancestry can be defined by one or multiple
sources. The definition given by Via et al. gives rise to a number of
downstream complications that have specific ramifications upon
both clinical practice and biomedical research.
One set of complications is methodological: if Via et al.
are correct that determinations of ancestry can be varied,
which will win out when one or more of these descriptions of
ancestry are in conflict? If ancestry can be determined by an
observer, how exactly does a clinician or biomedical researcher
become one without importing the flaws that the authors
find inherent in the use of either “race” or “ethnicity”? The
second set of complications is conceptual: What are the agreed-
upon classification schemes for biogeographical, geographical,
geopolitical, and cultural ancestry? How are they determined
given that from an empirical standpoint there is a large overlap
between the four aforementioned definitional levels? Is there a
hierarchical ordering of the definitional levels, and if so, what
ensures that we can make inferences of import for biomedical
and clinical outcomes between those levels and individuals? How
is the concept cultural ancestry, as used in biomedical research
and clinical contexts, supposed to work given that Via et al. note
that culture is categorically different than an individual’s genetic
background? Given the varied ways in which the term “ancestry”
has been used by researchers and clinicians themselves, and that
there is no coherent, operationalizable definition upon which
clinical and biomedical research has agreed, the use of “ancestry”
for anything of empirical import based on DTC products is in
serious doubt.
Indeed the term ancestry is inherently misleading, no actual
ancestral populations have been (or could be) sampled. The
methodological assumptions about past population “purity”
and “admixture” are just that—non-empirical assumptions
that are at odds with the reality that ancestral populations
(which DTC companies purport to report on) cannot be
sampled with accuracy. The direct-to-consumer tests at best
Frontiers in Medicine | www.frontiersin.org 3 March 2019 | Volume 6 | Article 48
Blell and Hunter “Genetic Ancestry” and Personalized Medicine
provide limited support for linking a consumer’s DNA profile
to places in which individuals whose DNA samples have
been analyzed and included in the company’s datasets lived
at the time of sampling. The reason why the information
generated by DTC companies provides limited support is due
to the underlying methodology of ancestry studies based on
populations. These programs are largely modeled after the
program STRUCTURE used in Rosenberg et al. (42, 44), even
though there is controversy as to whether STRUCTURE is
a reliable program for identifying genetic clusters (45). In
short, a baseline data set is generated by using samples from
contemporary individuals that have been carefully selected
on the basis that they themselves are members of a “pure”
or “non-admixed” population or a “pure” or “non-admixed”
individual. For individuals this would require, for example,
that the only people allowed to be part of a “non-admixed”
population are those whose four grandparents are also part of that
same population.
Of course, present-day patterns of residence are rarely
identical to what existed in the past due to historical events—
both social and natural—that have influenced patterns of
migration. Humans have migrated to such an extent that
many individuals around the world have relatively recent
ancestors from far-flung regions (46). As a result, databases of
present-day samples, regardless of reporting about grandparents,
can provide false leads (47). In addition, false assumptions
about the distinctiveness of populations in the past appear to
influence genetic ancestry analyses (46). As Duster notes, the
notion that a population group is “pure” or “non-admixed”
“is a statistical artifact that begins not with the DNA, but
with the researcher’s adopting of the folk categories of race
and ethnicity”(48). Given what is common knowledge about
evolutionary biology, there is no such thing as a “pure”
population in the mathematical sense. It is common knowledge
for demographers, epidemiologists, and other social scientists
that the terms used to describe racial/ethnic groups have
changed across time (49, 50), especially in particular contexts
like the UK and the USA, where the changes in official
racial/ethnic categories over time have been particularly stark.
If epidemiologists and other health practitioners are focused
on dealing with the patterns and causes of disease (e.g., Type
2 diabetes) across contexts, there will be a mis-match between
operationalized groups in different geo-political regions. The
people who count as “white” in one region may not neatly count
as “white” in another region or at another time period, thus
hampering the ability to detect valid and reliable epidemiological
relationships, much less associations of significance to direct
care (51).
The analytic techniques used in genetic ancestry tests clearly
focus on the small differences between current populations
rather than similarities between populations. Studies looking
to estimate genetic clustering have tended to choose samples
from places both more geographically and socially distinct
from one another. When samples have been collected using
more even geographical sampling, clustering has been “far
less evident” (46). This is because human genetic variation
is typically clinal. As Duster points out “when researchers
claim to be able to assign people to groups based on marker
frequency at a certain number of loci, they have chosen loci
that show differences between the groups they are trying
to distinguish.” Given that populations can be demarcated
by a number of criteria [see Kaplan and Pigliucci 2003
(52)], the focus upon difference is not only misleading about
human genetic variation (33) but helps to reproduce and
reinscribe the notion of biological race. A further complication
is that biases in sampling and analyses mean people living
in and coming from the Middle East, South Asia, Southeast
Asia, East Africa, and the Mediterranean region of Europe
are most likely to receive ancestry results which are less
valid, based on their known ancestry or any historical or
archaeological evidence (34, 41).
As distinct from these individual- consumer-focused
commercial practices, when inferences are made about ancestry
in academic research these are the level of the group and created
with measures reflecting their fundamentally probabilistic
nature (34). Indeed, due to the limitations of DNA itself,
regardless of technique, one would not be able to demonstrate
genetic links to many of one’s actual direct ancestors even
if they had been sampled so non-probabilistic measures are
impossible (34).
Genetic Ancestry Tests, Racialized Groups,
and Justice
It is worth highlighting the important implications of use of
genetic ancestry in terms of the ethical principle of justice in
medical practice. In particular, there are considerations specific
to racialized ethnic groups. While the concept of “justice”
can be construed and understood in quite a narrow way—
we wish to emphasize that there are historical and group-
level concerns for people who have been marginalized. With
respect to medical interventions, the examples of medical
injustices that have been perpetrated at the group level include
the Tuskegee Syphilis Study (53) and the Puerto Rican Birth
Control study (54).
Reinscription of the notion of biological race in medical
consultation, even inadvertently, validates the idea that race
and ethnicity are natural classifications and runs the risk of
encouraging racial/ethnic stereotypes and oversimplifications of
the complex origins of most disease, leading to both a naïve
genetic essentialism and a misunderstanding of human genetic
diversity in society (29, 46). In addition, the effective disregarding
of social production of health models of understanding the
ethnic patterning of ill-health, which have been developed on
the basis of epidemiological research over the past decades,
in favor of an assumption of a genetic basis, leaves ethnic
groups’ own supposedly shared faulty genes as the supposed
cause of their ill health. As legal scholar Roberts points out
“The biological explanation for racial disparities provides a ready
logic for the staggering disenfranchisement of people of color
through mass incarceration and other punitive policies, as well
as the perfect complement to color-blind policies implementing
the claim that racism has ceased to be the cause of their
predicament” (36).
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For their part, according to some reports, white supremacists
groups and individuals have seized genetic ancestry results and
publicly used these to argue for scientific racism when they
interpret the evidence as in favor of their ideology (55–57), while
working hard to delegitimizing any results which threatened
their self-identities (56). In the context of the rise of the far
right globally and recent reports of scientific racism and eugenics
in some of the world’s top ranked universities (58, 59), the
risk that doctors and medical systems may perpetuate injustice
cannot be ignored. Indeed, it has been found in previous
research that doctors often lack sufficient knowledge to tackle
misinformation associated with DTC genetic tests in general
(60, 61). Doctors may be like patients in failing to realize
that tests are probabilistic (41) and medical training may not
have prepared them with a detailed understanding of human
genetic variation (61).
CONCLUSION
Given the issues that we have highlighted above regarding
DTC products for assessing ancestry for biomedical and other
purposes, we wish to reiterate the following important points.
The first is that “ancestry estimates,” as currently described
in the literature, act as a reinscription of biological race. This
is because of the inherent confusion that abounds regarding
the concept “ancestry”—both for clinicians, biomedical
researchers, epidemiologists, population biologists, and
especially the general public. Since there are no principled,
operationalizable definitions of “ancestry” (nor “population”
for that matter), clinicians, biomedical researchers, and the
general public frequently project naive racial categories onto
their findings.
Secondly, it remains important to reiterate that medical
practitioners—the intermediaries between consumers and
potential medical interventions—have incredible obstacles that
prevent them from giving their patients a better assessment
and understanding of the “ancestry data” that are gleaned
from DTC products. In a recent survey by Baer et al. (62),
the authors noted that health researchers were “confused
about concepts of race and ethnicity and their link to genetic
differences between populations; many treated these concepts
as interchangeable and genetically based. . . [and] the younger
health researchers tended to put a stronger emphasis on the
genetic aspects of race than did the older health researchers”
(62). Couple this with the confusion over the concept of
“ancestry” that is exemplified by Via et al. and the statement
by prominent population biologist Neil Risch [2005] that he
“does not even know what race means,” and we can see there is
an incredibly dense conceptual field for medical practitioners
to attempt to sort out by themselves (63). Given the other
constraints on time and energy that are in play, we are loathe
to believe that this conceptual clarity will be absolved solely
by the community of practitioners that are swamped with
this morass.
Our final point is the following: the use of DTC products
for assessing the “ancestry” of individuals has a number
of ethical issues that are in urgent need of resolution.
It would have been better to have thought through and
dealt with these issues before the deployment of DTC
products rather than after: the ethical issues include potentially
providing misleading or inaccurate information that affects the
healthcare decisions by practitioners; confusion about differences
between ancestry and genealogy for consumers, clinicians, and
biomedical researchers; and the reintroduction of racialized
concepts under the guise of “genetic ancestry” which has
the potential for harming both individuals and marginalized
populations. We recommend that the professional bodies of
clinical practitioners (e.g., American Medical Association, the
Royal College of Physicians) and agencies evaluating medical
devices (e.g., FDA, European Medicines Agency) examine
the evidence we discuss here and consider issuing specific
guidance or warnings about use of genetic ancestry test
results in healthcare since these are not suitable for diagnostic
purposes and pose risks to individuals and society as we
outline above.
We have noted that DTC products are of interest to
consumers because of how they are marketed and what
they promise to potential users: Ancestry.com promises to
“Reveal the places you’re from”; in reference to their products,
23andme.com offer “Two easy ways to discover you.” The
promissory allure of helping people to “find themselves”
by giving a swab of their bodily tissue masks the fact
that there are conceptual inconsistencies, methodological
shortcomings, and ethical issues that influence whether
the general public thinks about personalized medicine as
racialized medicine.
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